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Prime-boostDevelopment of effective vaccines against highly pathogenic avian inﬂuenza (HPAI) H5N1 viruses is a global
public health priority. Considering the difﬁculty in predicting HPAI H5N1 pandemic strains, one strategy used
in their design includes the development of formulations with the capacity of eliciting broad cross-protective
immunity against multiple viral antigens. To this end we constructed a replication-defective recombinant
adenovirus-based avian inﬂuenza virus vaccine (rAdv-AI) expressing the codon-optimized M2eX–HA–
hCD40L and the M1-M2 fusion genes from HPAI H5N1 human isolate. Although there were no signiﬁcant
differences in the systemic immune responses observed between the intramuscular prime-intramuscular
boost regimen (IM/IM) and the intranasal prime-intramuscular boost regimen (IN/IM), IN/IM induced more
potent CD8+ T cell and antibody responses at mucosal sites than the IM/IM vaccination, resulting in more
effective protection against lethal H5N2 avian inﬂuenza (AI) virus challenge. These ﬁndings suggest that the
strategies used to induce multi-antigen-targeted mucosal immunity, such as IN/IM delivery of rAdv-AI, may
be a promising approach for developing broad protective vaccines that may be more effective against the
new HPAI pandemic strains.
© 2009 Elsevier Inc. All rights reserved.Introduction
The highly pathogenic avian inﬂuenza (HPAI) H5N1 virus has been
a considerable problem in Asia andmore recently in Europe. Repeated
outbreaks of HPAI H5N1 in Southeast Asia that resulted in the death of
poultry in the hundreds of millions pose a pandemic threat to human
health (Li et al., 2004; Subbarao et al., 1998). Since HPAI H5N1 was
ﬁrst shown to infect humans in 1997, more than 417 conﬁrmed
human infections (257 resulting in death) have been reported (WHO,
2009). Even though few cases resulting from human-to-human
transmission have been reported, most HPAI H5N1 infections in
humans have been due to exposure to infected poultry (Ungchusak et
al., 2005). Genetic assortment between human and avian inﬂuenza
viruses and/or mutations in HPAI H5N1 could result in the generationd at Division of Molecular and
nology, San 31, Hyoja-Dong,
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ll rights reserved.of inﬂuenza strains which could result in a new pandemic-associated
strain in human. Since human populations are immunologically naive
to the current HPAI H5N1 isolates the design of effective vaccines is an
urgent global public health priority (Hien, de Jong, and Farrar, 2004).
Currently available HPAI H5N1 vaccines are traditional egg-
produced inactivated vaccines. Despite several reports showing that
conventional inactivated whole H5N1 inﬂuenza virus vaccines could
induce cross-protective immunity, the reported cross-protection was
limited since they induced strain-speciﬁc neutralizing antibodies that
were ineffective against heterologous inﬂuenza virus strains (Bublot
et al., 2007; Kistner et al., 2007; Ninomiya et al., 2007). Furthermore,
several disadvantages are associated with the generation of inacti-
vated, egg-generated vaccines as follows: (i) the requirement for
biosafety level 3 containment facilities; (ii) lengthy generation times,
i.e., several months following the identiﬁcation of new potential
strains; (iii) HPAI H5N1 cannot be grown to high titers in eggs due to
their high pathogenicity; and (iv) some strains of HPAI H5N1 are only
modestly immunogenic (Treanor et al., 2006). Generating these
vaccines using traditional methods would not yield sufﬁcient
quantities for worldwide distribution for at risk populations in the
event of a pandemic. Therefore, alternative vaccine strategies that can
overcome these limitations are in demand.
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vector vaccines, recombinant proteins, virus-like particles and DNA
vaccines, have been extensively studied as alternative approaches
(Horimoto and Kawaoka, 2006). Included in the list of alternative
strategies are the replication-defective recombinant adenoviral vector
(rAdv)-based vaccines. rAdv-based vaccines have been widely used in
preclinical and clinical studies and proven to be a safe and effective
vaccine vector (Bangari and Mittal, 2006; Priddy et al., 2008; Van
Kampen et al., 2005). In addition, rAdv-based vaccines do not require
biosafety level 3 containment facilities and are much easier to
stockpile than traditional egg-produced inactivated vaccines. Fur-
thermore, recent reports showed that a replication-defective rAdv-
based avian inﬂuenza vaccines were very effective in animal models
of infection (Epstein et al., 2005; Gao et al., 2006; Hoelscher et al.,
2006; Hoelscher et al., 2007; Holman et al., 2008; Tompkins et al.,
2007; Toro et al., 2007; Toro et al., 2008) suggesting that an rAdv-
based HAPI vaccine is a logical alternative to traditional egg-derived
vaccines.
Since mucosal surfaces are primary sites utilized by numerous
pathogens (including inﬂuenza virus) as portals of entry, mucosal
immune responses (including secretory IgA antibody [Abs] produc-
tion and cytotoxic T cell responses) at mucosal sites are thought to
play crucial roles in host protection against mucosal pathogens (Kilian
and RM, 1999). However, current intramuscular delivery of inacti-
vated inﬂuenza vaccines is less effective at inducing mucosal
immunity (Cate et al., 1983; Clements and Murphy, 1986). Most
rAdv-based inﬂuenza virus vaccines mentioned above are also
delivered via intramuscular injection; however, this formulation has
the capacity to induce mucosal immune responses (Baig et al., 2002)
suggesting that mucosal immunization with the same formulation is
likely to elicit a more potent response at this critical host–pathogen
interface. Adenovirus can invade host cells via mucosal surfaces and
replicate (initially at mucosal sites of the respiratory or gastrointes-
tinal tracts) supporting the use of rAdv-based vaccines as a substitute
to current vaccines.
An ideal pre-pandemic or pandemic inﬂuenza vaccine should
possess the ability to generate broad protective immunity at both
systemically and mucosal sites. In this study, we generated a rAdv-
based inﬂuenza virus vaccine (rAdv-AI) expressing the codon-
optimized M2eX–HA–hCD40L and M1–M2 fusion genes from HPAI
H5N1 human isolates for the development of a broadly protective
vaccine. We investigated whether the vaccination route (systemic vs.
mucosal) would affect mucosal and/or systemic immune responses in
addition to assessing the protection efﬁcacy following a challenge
with lethal H5N2 avian inﬂuenza (AI) virus. We demonstrated that
the intranasal prime-intramuscular boost (IN/IM) vaccination regi-
men induced more potent anti-AI-speciﬁc mucosal immunity associ-
ated with better protection against challenge with lethal H5N2 avian
inﬂuenza virus in mice compared to the intramuscular prime-
intramuscular boost (IM/IM) vaccination regimen.
Results
The generation of a rAdv-AI vaccine expressing multiple antigens
To elicit broad protective immunity, a vaccine should induce both
humoral and cellular immune responses to conserved target
antigens, e.g., M1 and M2. M1 is highly conserved and is the
inﬂuenza virus protein produced in the greatest abundance.
Furthermore, the M158–66 sequence was shown to be a dominant
CTL epitope in HLA-A2+ individuals and is well conserved even in
HPAI H5N1 strains (Bednarek et al., 1991; Gianfrani et al., 2000; Ito
et al., 1991). The sequence of the M2 24-amino acid ectodomain
(M2eX) is relatively well conserved compared to hemagglutinin (HA)
and neuraminidase (NA) which are the major targets of the current
egg-based, inactivated vaccines. Furthermore, M2eX-speciﬁc anti-bodies were shown to reduce morbidity by restricting viral
replication (Fan et al., 2004; Liu et al., 2004; Zharikova et al.,
2005). In addition, fusion of the extracellular domain of CD40L to
antigens enhanced immune responses by targeting secreted antigens
to antigen presenting cells (APCs) such as dendritic cells (DCs) via
the interaction with CD40 on their surfaces (Li, 2005; Zhang et al.,
2003). Finally, we used a dually-regulated expression cassette using
internal ribosome entry site (IRES) which is the most commonly used
multiple gene transfer approach (Martinez-Salas, 1999) for the
generation of multigene-expressing rAdv vaccines in a single vector
(Fig. 1A). The expression of encoded proteins by rAdv-AI was veriﬁed
by Western blot analysis of rAdv-AI-infected QBI293 cells. As shown
in Fig. 1B, about 95 and 42 kDa bands corresponding tpa–M2eX3–HA
(ecd)–CD40L(ecd) and tpa–M1–M2 fusion proteins, respectively,
were detected in rAdv-AI-infected QBI293 cell lysates, but not in
control cell lysates.
Comparison between systemic and mucosal rAdv-AI vaccination routes
on T cell-mediated immunity in mice
To compare the effectiveness of systemic and mucosal T cell-
mediated immunity following systemic or mucosal immunization
with rAdv-AI using a prime-boost regimen, HLA.A2 transgenic (Tg)
and Balb/c (H-2d) mice were immunized twice at 2-week intervals
with rAdv-AI via the IM/IM vaccination regimen or the IN/IM
vaccination regimen. Since the M158–66 (HLA.A2-restricted epitope)
and the HA149–163 (H-2Kd-restricted epitope) of human inﬂuenza
virus are conserved in the HPAI H5N1 strains used for our vaccine,
CD8+ T cell responses to these epitopes using splenocytes or cells
from lung washes were evaluated. In HLA.A2 Tg mice, the IM/IM
vaccination regimen induced higher level of M1-speciﬁc CD8+ T cell
responses in spleen, compared to IN/IM vaccination regimen (Fig. 2).
These results were consistent with previous reports showing that the
IM immunization with rAdv encoding HA gene elicited higher
systemic CD8+ IFN-γ responses than the IN vaccination (Hoelscher
et al., 2006). In contrast to systemic T cell-mediated responses, the
IM/IM regimen did not induce M1-speciﬁc CD8+ T cell responses at
mucosal sites (Fig. 2B). While there were few inﬁltrating CD8+ T cells
identiﬁed following vaccination via the IM/IM vaccination regimen
(Fig. 2B-1, upper left panel), more lung-inﬁltrated CD8+ T cells were
detected and 20.5% of the lung-inﬁltrating CD8+ T cells were M1-
speciﬁc IFN-γ-secreting CD8+ T cells in the IN/IM vaccination group.
Similar patterns of results were obtained in Balb/c mice (Fig 3). The
IM/IM vaccination regimen induced higher level of M1 (M1 peptide
pool)- and HA (HA149–163)-speciﬁc CD8+ T cell responses in spleen in
Balb/c mice (Fig. 3A). In terms of CD8+ T cell responses at mucosal
site, few lung-inﬁltrated CD8+ T cells were detected in the IM/IM
group (Fig. 3B-1, upper panel), but more lung-inﬁltrated CD8+ T cells
were detected and ∼0.82% of them were HA-speciﬁc CD8+ T cells in
IN/IM group (Fig 3B). Taken together, while the IM/IM regimen
induced higher systemic CD8+ T cell responses, compared to the IN/
IM vaccination regimen, the IN/IM vaccination regimen elicited more
efﬁcient T cell-mediated responses against M1 and HA at mucosal
sites compared to the IM/IM vaccination regimen.
Comparison between humoral responses following systemic or mucosal
rAdv-AI vaccination
To compare humoral immunity following either systemic or
mucosal rAdv-AI immunization, sera and lung washes from Balb/c
mice immunized using the two regimens were collected and analyzed
to determine HA- and M2eX-speciﬁc IgG and IgA responses by
endpoint dilution ELISA (Fig. 4). When we compared the primary
antibody responses after the ﬁrst injection of rAdv-AI delivered either
IM or IN (Fig. 4, 2 weeks after ﬁrst immunization in serum) both
regimens induced comparable levels of serum anti-M2eX-speciﬁc IgG
Fig. 2.M1-speciﬁc CD8+ T cell responses in HLA.A2 transgenic mice. HLA.A2 transgenic mice were primed intramuscular injection (IM) or intranasal injection (IN) and boosted (IM)
at 2-week interval with 5 × 106 pfu of rAdv-EGFP or rAdv-AI. Four weeks after the ﬁnal immunization, mice were sacriﬁced to measure M158–66-speciﬁc CD8+ T cell responses by
ELISPOT assay (A) and FACS analysis (B) using cells from lung wash and spleen (ﬁve mice per group). Data are presented as mean±SEM (A) and (B-2) and as representative density
plots (B-1). Numbers in quadrants indicate the percentages of IFN-γ-secreting cells over total CD8+ T cells. Statistical signiﬁcance was determined using the Student's t-test. SFCs,
spot forming cells.
Fig. 1. Schematic diagrams of a recombinant adenovirus vaccine. (A) Codon-optimized tpa–M2eX3–HA(ecd)–CD40L(ecd) and tpa–M1–M2 genes were cloned into an E1/E3-deleted
replication-defective adenoviral vector and the recombinant adenovirus-based vaccines were produced as described in Materials and methods. Ecd, extracellular domain; IRES,
internal ribosome entry site; LITR, left inverted terminal repeats; RITR, right inverted terminal repeats; E.S., encapsidation signal. (B) The expression of tpa-M2eX3-HA-CD40L fusion
protein (left panel) and Matrix (right panel) from rAdv-AI was veriﬁed by Western blot analysis. QBI293 cells were infected with rAdv-AI at MOI 10. After 48 h, heat-denatured cell
lysates were subjected to 10% SDS–PAGE and Western blots analysis with anti-CD40L and anti-M1 antibodies. Molecular markers are shown on the left and the right, respectively.
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Fig. 3. Comparison of cellular immune responses depending on immunization route in Balb/c mice. Balb/c mice were primed (IM or IN) and boosted (IM) at 2-week interval with 1 ×
108 pfu of rAdv-EGFP or rAdv-AI. Four weeks after the ﬁnal immunization, mice were sacriﬁced to measure (A-1) M1-speciﬁc and (A-2) HA149–163-speciﬁc CD8+ T cell responses by
ELISPOT assay and HA149–163-speciﬁc CD8+ T cell responses in lung by FACS analysis (B) using cells from lung wash and spleen (three to six mice per group). Data are presented as
mean±SEM (A) and (B-2) and as representative density plots (B-1). Numbers in quadrants indicate the percentages of IFN-γ-secreting cells in CD8+ T cells. IM and IN stand for
intramuscular immunization and intranasal immunization, respectively. Statistical signiﬁcance was determined using the Student's t-test. SFCs, spot forming cells.
185K.S. Park et al. / Virology 395 (2009) 182–189and IgA antibodies. These serum antibody responses were further
increased following secondary immunization (Fig. 4, 4 weeks after
second immunization in serum). The levels of HA- andM2eX (H5N1)-
speciﬁc IgG and IgA responses in serum following IN/IM vaccination
were higher than responses observed following the IM/IM vaccina-
tion regimen.
In contrast to systemic humoral responses, mucosal anti-HA and
-M2eX IgA and IgG responses in the lung following the IN/IM
vaccination regimen were signiﬁcantly higher than the responses
observed in animals receiving the IM/IM vaccination regimen (Fig.
4, 4 weeks after second immunization in lung). Consistent with
previous report (Lemiale et al., 2003), IM/IM-immunized mice did
not develop potent mucosal IgA responses (Figs. 4B, D and F).
Overall, these results suggested that the IN/IM vaccination regimen
induced higher mucosal and systemic humoral responses than
responses observed in mice immunized via the IM/IM vaccination
regimen.
The effect of the rAdv-AI vaccination route on protection efﬁcacy
To evaluate the protective efﬁcacy of rAdv-AI in immunized Balb/c
mice, 12 mice per group were immunized twice at 2-week intervals
via the IM/IM or IN/IM vaccination routes followed by a challenge
with a LD50 of H5N2 AI virus (A/aquatic bird/Korea/w81/2005) (IN)
4 weeks after the ﬁnal immunization. Control mice immunized with
buffer alone suffered substantial weight loss beginning 2 days post-
challenge (dpc) and died at 5–7 dpc (Fig. 5). Although ∼60% of the IM/
IM-immunized mice survived, mice in this group exhibited substan-
tial weight loss similar to that observed in the control group up to 4dpc. In contrast, all mice in the IN/IM vaccine group were 100%
protected and these animals presented with only mild and transient
weight loss. The protective efﬁcacy of this vaccination strategy
correlated with the mucosal immune response, indicating that the
IN/IM regimen conferred signiﬁcantly better protection against
challenge than the IM/IM vaccination regimen due to the ability of
this vaccination strategy to induce stronger mucosal immune
responses.
Despite partial (IM/IM) or complete (IN/IM) protection, the
antibody responses against HA antigen of the challenge virus elicited
following rAdv-AI vaccination were below detectable levels when
measured by HI assay (Table 1), possibly due to sequence differences
between HAs of the vaccine and the challenge virus groups
(sequence identity: 93%). In contrast, in terms of HI titers against a
H5N1 AI virus (A/environment/Korea/W150/2006), which has
higher sequence homology (∼97% of HA sequence identity), both
regimens induced about ∼40 HI titers (Table 1). However, IN/IM
regimen induced HI titers in more mice than IM/IM regime (10/10
and 2/10, respectively).
These results suggested that even without detectable antibody
levels to HA, the multi-antigen-targeted rAdv-AI vaccine induced
protective immunity against antigenically distinct AI virus challenge.
This protective immunity may be (in part) due to T cell responses
mounted against conserved regions of viral protein antigens, e.g., the
matrix region (sequence identity of M1: 96%), and speciﬁc anti-M2eX
antibody responses resulting in the protection of mice from challenge
as a result of viral replication inhibition. It is worth noting that M2eX-
speciﬁc immune responses elicited by rAdv-AI vaccinationwere cross-
reactive to the M2eX sequence of the challenge virus despite some
Fig. 4.HA- andM2eX-speciﬁc humoral responses. Balb/c mice were primed (IM or IN) and boosted (IM) at 2-week interval with 1 × 108 pfu of rAdv-EGFP or rAdv-AI. Six weeks after
the ﬁrst immunization, sera were taken and tested by endpoint dilution ELISA for (A and B) HA (H5N1), (C and D) M2eX3 (H5N1), and (E and F) M2eX3 (H5N2)-speciﬁc antibody
responses. An ELISA Ab titer was expressed as the highest serum dilution giving a positive reaction. The Ab-positive cut-off values were set as mean + 3 SD of non-immunized sera.
Statistical signiﬁcance was determined using the Student's t-test. (A, C and E) IgG titers. (B, D and F) IgA titers.
186 K.S. Park et al. / Virology 395 (2009) 182–189sequence differences (i.e., vaccine: SLLTEVETPTRNEWESRSSDSSD and
SLLTEVETPTRNEWECRCSDSSD vs. H5N2 challenge virus: SLLTE-
VETPTRNGWECKCSDSSD) (Figs. 4E and F).
Discussion
In this study, we developed a replication-defective recombinant
adenovirus-based avian inﬂuenza virus vaccine (rAdv-AI) encoding
the codon-optimized M2eX–HA–hCD40L and the M1–M2 gene
fusion from the HPAI H5N1 human isolate. We assessed the
effectiveness of systemic and mucosal vaccination on immune
induction in the context of protection following viral challenge.
Systemic rAdv-AI intramuscular prime-intramuscular boost (IM/IM)
immunization induced serum humoral and splenic T cell responses
but not humoral or T cell responses at mucosal sites (Lemiale et al.,
2003; Wang et al., 2004). In contrast, not only systemic but potent
mucosal immune responses were induced following an intranasal
prime-intramuscular boost (IN/IM) vaccination regimen (Figs. 2–4).
Furthermore, the IN/IM vaccination regimen conferred complete
protection against lethal H5N2 AI virus challenge, compared to
partial protection in the IM/IM vaccination group (Fig. 5). Since it is
difﬁcult to predict pandemic strains, vaccines with the capacity of
eliciting broad protective immunity may be suitable. Thus, challenge
with an antigenically distinct strain, such as H5N2 strain, may be a
possible way to evaluate broad protective immunity of our vaccine
regimen.Previous reports using parenterally administered rAdv-based
inﬂuenza virus vaccines only examined systemic immune responses
(Gao et al., 2006; Hoelscher et al., 2006). Although these reports
showed the induction of strong systemic immunity conferring
complete protection against homologous and heterologous AI
infection, mucosal immunity plays a critical role in protection against
infection with many pathogens including inﬂuenza virus (Kilian and
RM, 1999; Lefrançois, 2005). As shown in this study, administration of
rAdv-AI using the IN/IM vaccine regimen not only induced potent
mucosal immunity but also elicited systemic humoral and T cell-
mediated immune responses.
In the context of protection against infections, the conventional
IM/IM regimen did not confer complete protection (∼60% survival
rate) which is inconsistent with previous reports showing that
systemic immunization with rAdv-based inﬂuenza virus vaccines
expressing HA could induce complete protection against lethal AI
virus challenge (Gao et al., 2006; Hoelscher et al., 2006). In addition,
Hoelscher et al. (2007) showed a similar protective efﬁcacy between
IM and IN vaccination strategies. This discrepancy may be due to
differences in the experimental design, challenge virus strain used
and the dose of the challenge virus. In one study the immunizing and
challenge virus were homologous, i.e., the HA amino acid identity
between the vaccine strain and the challenge strain was ∼96%
(Hoelscher et al., 2007). In our study, the amino acid identity was
only 93%. Furthermore, the HI titers against H5N2 challenge virus
were below the detection level. Thus, our test conditions for
Fig. 5. Protective efﬁcacy to heterologous AI (H5N2) challenge. Balb/c mice were
primed (IM or IN) and boosted (IM) at 2-week interval with 1 × 108 pfu of rAdv-AI.
Four weeks after the ﬁrst immunization, all mice were intranasally challenged with
LD50 of lethal avian inﬂuenza virus (H5N2). After challenge, (A) percentage of initial
weightand (B) survival rate were followed up every day. Average percentage of initial
weight is expressed as a percentage of the weight of the examined day over the original
weight. Data shown are the means for 12 mice per group. Analysis of survival was
conducted by a log-rank test.
187K.S. Park et al. / Virology 395 (2009) 182–189protective immunity may be stricter. Thus, it is still valid that IN/IM
delivery may be more effective if broad protective immunity is
needed.We also found that the IM/IN and IN/IN vaccination regimens
conferred similar levels of protection compared to the IN/IM
vaccination regimen (data not shown). The IN/IN vaccination
regimen was the most effective at inducing mucosal T cell-mediated
and systemic immune responses as well as mucosal humoral
responses. Immunity elicited following the IM/IN vaccine regimen
was comparable to the responses elicited following the IN/IM vaccine
regimen. Accordingly, mucosal immunization appeared to be a
suitable route for the induction of both mucosal and systemic
immune responses and should be considered in the design of vaccines
requiring both types of immune responses.
Interestingly, the rAdv-AI vaccine did not elicit a neutralizing
humoral response against an H5N2 AI virus but provide completeTable 1
HI titers (GMT)a
H5N1 H5N2
rAdv-EGFP (IM/IM) b20 (0/10) b20 (0/10)
rAdv-EGFP (IN/IM) b20 (0/10) b20 (0/10)
rAdv-AI (IM/IM) 40 (2/10) b20 (0/10)
rAdv-AI (IN/IM) 49 (10/10) b20 (0/10)
a The geometric mean HI antibody titers against H5N1 virus (A/environment/Korea/
W150/2006) or H5N2 virus (A/aquatic bird/Korea/w81/2005) are expressed as the
reciprocal of the highest dilution of sera that inhibited hemagglutination. The numbers
of positive sera are indicated in parentheses (number of positive sera/total number of
sera). GMT, geometric mean reciprocal endpoint titer.protection against a lethal H5N2 AI virus challenge suggesting that T
cell and M2eX-speciﬁc antibody responses played a critical role in the
conferring protection. Since our rAdv-AI vaccine encodes matrix as
well as HA, a possible mechanism resulting in protection against
H5N2 AI virus challenge may involve M1- and HA-speciﬁc T cell-
mediated responses recognizing conserved regions. This is consistent
with other studies that demonstrated that M1-speciﬁc CTLs and
M2eX-speciﬁc antibodies were cross-protective against different
human inﬂuenza A virus subtypes (Fan et al., 2004; Jameson, Cruz,
and Ennis, 1998; Liu et al., 2004; McMichael et al., 1983; Zharikova
et al., 2005). In addition, two recent studies have demonstrated that
protection elicited following vaccination with an rAdv-based inﬂu-
enza virus HA-expressing vaccine against an AI virus challenge
occurred in the absence of neutralizing humoral immunity (Gao
et al., 2006; Hoelscher et al., 2006; Hoelscher et al., 2007). Gao et al.
have shown the presence of heterotypic H5N1 protection in the
absence of neutralizing humoral responses and partial protection
from homologous H5N1 challenge following vaccination with a rAdv-
based HA2 vaccine (the HA2 region is known not to induce
neutralizing humoral responses). Similarly, Hoelscher et al. have
shown that immunized mice had neutralizing anti-HI antibodies
below the levels of assay detection but that these mice were still
completely protected, i.e., no loss of body weight and 100% survival.
Our data also showed that mice that received rAdv-AI did not
develop HI titers against H5N2 challenge virus even though amino
acid sequence identity of the HA sequence between the vaccine and
challenge virus was 93%. However, mice that received the rAdv-AI
vaccine still were completely protected against a lethal H5N2
challenge. Taken together, these data suggested that protection
against an H5N2 lethal challenge in the absence of HI titers can be
facilitated by other mechanisms, namely, cell-mediated immunity or
non-hemagglutinating antibodies, possibly by antibody-dependent
cell-mediated cytotoxicity.
Although adenoviral vectors have proven their potency in
numerous previous studies, pre-existing immunity to human adeno-
viruses could be a potential problem in the adenoviral vector-based
vaccine ﬁeld. In a recent report, however, an inﬂuenza vaccine trial
found that there was no correlation between the levels of pre-existing
Ad5-neutralizing antibody titers and the potency of the intranasally
administered Ad5-based vaccine (Van Kampen et al., 2005). In
addition, data from a phase I/II HIV vaccine trial sponsored by NIH
Vaccine Research Center show that while pre-existing immunity to
Ad5 does impact the performance of the Ad5-based HIV vaccine, this
limitation can be overcome by increasing the dose of the vaccine
(Catanzaro et al., 2006). Additionally, there is experimental evidence
that vaccination through alternate routes of administration (such as
oral or intranasal) (Appaiahgari et al., 2006; Xiang et al., 2003) and
alternate vectors derived from rare human adenovirus or non-human
adenovirus can overcome pre-existing vector immunity.
In this study, we demonstrated several advantages of the mucosal
prime-systemic boost regimen using an adenoviral vector-based
vaccine in terms of eliciting both mucosal and systemic immunity
since this approach conferred protection against an antigenically
distinct AI virus challenge. These data suggest that this strategy is a
promising approach for the development of novel vaccines capable of
preventing and controlling highly pathogenic H5N1 avian inﬂuenza
virus infections.
Materials and methods
Peptides
M158–66 (GILGFVFTL), HA149–163 (SACPYQGKSSFFRNV), M2eX-H5N1
(SLLTEVETPTRNEWESRSSDSSD), M2eX-H5N2 (SLLTEVETPTRNG-
WECKCS DSSD) and overlapping peptides spanning the full length
of M1 were synthesized by PEPTRON, Inc. (www.peptron.com).
188 K.S. Park et al. / Virology 395 (2009) 182–189Gene synthesis and replication-defective recombinant adenovirus
construction
The codon-optimized tpa–M2eX3–HA–hCD40L and tpa–M1–M2
fusion genes were synthesized by Bio S and T, Inc. (www.Biost.
com). The signal sequence of tPA (tissue plasminogen activator)
was fused to the 5′ end of each of the fusion genes. Three copies
of M2eX (2–24 amino acids of M2) sequences were linked by a
Gly-Ser-Gly linker (SLLTEVETPTRNEWESRSSDSSD-GSG-SLLTE-
VETPTRNEWESRSSDSSD-GSG-SLLTEVETPTRNEWECRCSDSSD-GSG)
and the extracellular domain regions of the HA gene from the HPAI
H5N1 human isolate, A/Hong Kong/213/2003 (HK/213/03), and
human CD40L were used. The HA gene signal sequence was also
deleted. The HPAI H5N1 human isolate M1 and M2 genes from A/
Vietnam/1203/2004 (VN/1203/04) were linked by Gly-Ser-Gly-Ser-
Gly-Ser-Gly-Ser-Gly-Ser-Gly-Ser. The two genes were linked (fused)
by IRES of encephalomyocarditis virus and the ﬁnal tPA–M2eX3–
HA–hCD40L–IRES–tpa–M1–M2 gene was cloned into a shuttle
vector with tetracycline-responsive elements. As shown in Fig. 1A,
an E1/E3-deleted replication-defective adenoviral vector (Qbiogene,
Inc.) expressing the multi-antigens (rAdv-AI) was generated by
recombination in BJ5183, propagated in 293 Trex cells (Invitrogen
Co.) and puriﬁed by double CsCl (discontinuous and continuous)
centrifugations and dialysis according to the manufacturer's instruc-
tions. The concentration of the resultant recombinant adenoviral
vaccine was determined by the tissue culture infectious dose 50
(TCID50).
Western blot analysis
To verify the expression of the two fusion proteins (the tPA–
M2eX3–HA–hCD40L and the tpa–M1–M2), QBI293 cells (Qbiogene,
Inc.) which contain the E1A and E1B Ad5 viral genes were infected
with rAdv-AI or rAdv-EGFP at a multiplicity of infection (MOI) of 10.
At 48 h post-infection, cells were harvested, resuspended in
phosphate buffered saline (PBS), mixed with an equal volume of 2×
sodium dodecyl sulfate (SDS) sample buffer (125 mM Tris–HCl, pH
6.8, 4% SDS, 20% glycerol, 0.01% bromophenol blue and 10% β-
mercaptoethanol), boiled for 10 min, separated on an 8% SDS–
polyacrylamide gel electrophoresis (PAGE) gel and transferred onto
nitrocellulose membranes. Detection of expressed proteins, tPA–
M2eX3–HA–hCD40L and tpa–M1–M2, was conﬁrmed by probing the
blots with anti-human CD40 ligand (Santa Cruz Biotechnology, Inc.)
or anti-M1 (Santa Cruz Biotechnology, Inc.) antibodies, respectively
(Fig. 1B).
Immunization and challenge
Six- to 8-week-old HLA.A2 transgenic (Tg) or Balb/c mice were
primed IM or intranasally IN and boosted IM at 2-week intervals with
5×106 plaque forming units (pfu) (HLA.A2 Tg) or 1×108 pfu (Balb/c)
of rAdv-AI under anesthesia. For IM immunization, micewere injected
with 50 μl of rAdv-AI into each quadriceps muscle. IN immunizations
were performed by lightly anesthetizing the mice with a 200 μl
intraperitoneal (IP) injection of ketamine (100mg/kg of bodyweight;
Yuhan Co.) and xylazine hydrochloride (10 mg/kg of bodyweight;
Bayer) in PBS, and then applying 30 μl of rAdv-AI into each nostril via a
micropipette. Sera were collected at 2 and 6 weeks after priming and
some mice were sacriﬁced for mucosal and systemic immunological
analysis at 6 weeks after priming. Lung washes were collected by
repeated ﬂushing using an intra-tracheal injection of 1 ml PBS at the
time of sacriﬁce. At 4 weeks after the ﬁnal vaccination, Balb/c mice
were anesthetized and challenged IN with a 50% lethal dose (LD50) of
antigenically heterologous avian inﬂuenza (AI) virus strain (A/aquatic
bird/Korea/w81/2005, H5N2) or homologous AI virus strain (A/
environment/Korea/W150/2006, H5N1). The challenge viruses werekindly provided by Dr. Young Ki Choi of Chungbuk National
University.
Anti-M2eX and anti-HA antibody ELISAs
Ninety-six-well immunoplates (Nunc) were coated with 50 μl of
either M2eX-H5N1 (2 μg/ml), M2eX-H5N2 (2 μg/ml) or HA protein
(0.5 μg/ml) diluted in PBS. After overnight incubation at 4 °C, the
plates were blocked with 5% non-fat milk in PBST (PBS–0.05% Tween-
20; Sigma-Aldrich Co.) for 1 h at room temperature (RT). Sera and
lung washes were serially diluted in 5% non-fat milk in PBST. Sera and
lung wash dilutions were added to the coated plates and incubated
overnight at 4 °C. Plates were then washed ﬁve times with PBST and
incubated with horseradish peroxidase (HRP)-conjugated anti-mouse
IgG (1:3000; Southern Biotech) or anti-mouse IgA (1:3000; Santa
Cruz Biotechnology, Inc.) for 1 h at RT. Plates were washed seven
times and 50 μl of TMB substrate (Sigma-Aldrich Co.) was added to
each well. The reaction was stopped after 30 min by the addition of
50 μl of 2N H2SO4. The optical density at 450 nm (OD 450) was
measured with an ELISA plate reader (Bio-Tek instruments). ELISA
endpoint titers were expressed as the highest dilution that yielded an
optical density greater than the mean plus three times standard
deviation of a similarly-diluted negative control sample.
Intracellular IFN-γ staining assay
To determine the number of inﬂuenza-speciﬁc IFN-γ-producing
cells, cells from spleens and lungs were washed, stimulated with the
indicated peptides (10 μg/ml) for 6 h at 37 °C in the presence of
brefeldin A, washed, surface-stained with anti-CD8 antibody at 4 °C
and ﬁxed/permeabilized using the ﬁx/perm solution (FACSLyze, BD
Scientiﬁc) diluted to 2× with distilled water, 0.05% Tween 20 (Sigma-
Aldrich, Co). Cells were washed once and incubated at room
temperature with PE-conjugated antibodies speciﬁc for IFN-γ. Cells
were washed and resuspended in PBS containing 1% paraformalde-
hyde. Dead cells were excluded on the basis of forward and side light
scatter using a CellQuest (BD Biosciences) ﬂow cytometer. All
ﬂuorochrome-conjugated monoclonal Abs were purchased from BD
PharMingen.
IFN-γ ELISPOT assay
IFN-γ ELISPOT assays were performed as previously described (Lee
et al., 2005). The indicated peptide (10 μg/ml) was used as a
stimulator. IFN-γ ELISPOT responses to media controls were sub-
tracted from the responses to the stimulators. Results are expressed as
the average number of IFN-γ-secreting cells (SFCs) per indicated
splenocytes.
HI assay
The HI assay was performed as described previously (Lee et al.,
2009). Brieﬂy, H5N1 virus (A/environment/Korea/W150/2006) or
H5N2 virus (A/aquatic bird/Korea/w81/2005) was diluted to contain
4 agglutinating U in PBS. The diluted viruses were incubated with
serial twofold dilutions of receptor-destroying enzyme-treated serum
samples, startingwith a 1:20 dilution at room temperature for 30min.
The antigen–antibody mixtures were tested for HA activity by the
addition of 0.5% chicken red blood cells to determine the HI titers. The
results are the geometric mean titers of positive sera (≥20).
Statistical analysis
All data are representative of at least more than two different
experiments. To measure statistical differences between groups, a
Student's t-test was used. The difference in survival rates between
189K.S. Park et al. / Virology 395 (2009) 182–189groups was analyzed using a log-rank test. For all comparisons,
differences were considered signiﬁcant when the p values were
b0.05.
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